Impact of Ketoflex 12/3 Diet on Early-to-Mid Stage Alzheimer's Progression

Effects of Concurrent Plant-Based Ketogenic Diet and Intermittent Fasting (Ketoflex 12/3) on the Clinical Progression of Early-to-Mid Stage Alzheimer's Dementia

This study investigates the effects of the Ketoflex 12/3 diet on the clinical progression of early-to-mid stage Alzheimer's disease. The study evaluates cognitive function, metabolic changes, and overall health outcomes in participants following the Ketoflex 12/3 dietary protocol.

Inclusion Criteria:

• Age between 50-85 years
• Clinical Dementia Rating (CDR) score of 1 or2
• Diagnosis of Alzheimer's disease (AD) according to NIA-AA criteria

Exclusion Criteria:

• Alcohol and/or substance dependence
• Diagnosis of chronic renal failure
• Diagnosis of another neuropsychiatric disorder
• Presence of amalgam dental fillings and/or failure to have them removed following the SMART protocol